You are here
UK Patients Won’t Benefit From GW Pharma’s Expansion activism 

UK Patients Won’t Benefit From GW Pharma’s Expansion

UK medical cannabis company GW Pharmaceuticals is planning a massive expansion in Britain. This growth is necessary to meet the anticipated demand for a new epilepsy treatment, after promising results in clinical trials.

The company plans to hire 70 new staff members and invest approximately £50m in capital funding over the next three years.

“We’re proud to be a UK company,” said Adam George, UK Managing Director of GW Pharmaceuticals. “We do all our manufacturing in the UK and we are scaling up, ready to commercialize [the new product] next year.”

Read the full article

Related posts